Drugs / Chromium Picolinate

Trials 7 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00332085 Jan 2006 → Mar 2007 type 2 diabetes mellitus Bastyr University Terminated No outcome recorded
Phase 41 trial
Phase 4 NCT00283777 Aug 1998 → Jan 2003 type 2 diabetes mellitus Pennington Biomedical Research Center Completed No outcome recorded
Phase not applicable5 trials
NCT07371169 Jan 2025 → Jan 2026 acanthosis nigricans Uruk University Completed No outcome recorded
NCT00477854 Apr 2005 → May 2007 atypical depressive disorder, obesity disorder Pennington Biomedical Research Center Completed No outcome recorded
NCT00128154 Jan 2004 → Dec 2005 metabolic syndrome X, obesity disorder, prediabetes syndrome National Center for Complementary and Integrative Health (NCCIH) Completed No outcome recorded
NCT00308451 Nov 2003 → Apr 2004 type 2 diabetes mellitus Nutrition 21, Inc. Completed No outcome recorded
NCT00289354 Mar 2003 → Nov 2005 type 2 diabetes mellitus Nutrition 21, Inc. Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as Chromium picolinate ClinicalTrials.gov intervention name — accepted as the source's own label NCT00128154
6

NCT00289354

NCT00283777

NCT00308451

NCT00332085

NCT00477854

NCT07371169

Known as CrPic “The objective of this study was to determine the effects of chromium picolinate (CrPic) on glucose metabolism in patients with metabolic syndrome.” PMID 19422140 Apr 2009
Modality Other / unclassified “Chromium is an essential mineral that is used in the breakdown of fats, protein, and carbohydrates.” NCT00128154
Route Oral “Participants in this arm (n=45) will recieve oral Chromium Picolinate 200mcg capsules once daily during the 24-weeks study period.” NCT07371169